



UKHSA publications gateway number: GOV-20206

Measles, mumps, rubella and varicella (MMRV) vaccine Patient Group Direction (PGD)

This PGD is for the administration of measles, mumps, rubella and varicella (MMRV) vaccine to individuals from one year of age and eligible for routine or catch-up immunisation, or from 9 months of age if early protection is required against varicella.

This PGD is for use by registered healthcare practitioners identified in [section 3](#), subject to any limitations to authorisation detailed in [section 2](#).

Reference no: MMRV vaccine PGD
Version no: v2.0
Valid from: 20 January 2026
Review date: 31 May 2028
Expiry date: 30 November 2028

The UK Health Security Agency (UKHSA) has developed this PGD to facilitate the delivery of publicly funded immunisation in England in line with national recommendations.

Those using this PGD must ensure that it is organisationally authorised and signed in [section 2](#) by an appropriate authorising person, relating to the class of person by whom the product is to be supplied, in accordance with Human Medicines Regulations 2012 (HMR2012)¹. **The PGD is not legal or valid without signed authorisation in accordance with [HMR2012 Schedule 16 Part 2](#).**

Authorising organisations must not alter, amend or add to the clinical content of this document (sections 4, 5 and 6); such action will invalidate the clinical sign-off with which it is provided. In addition, authorising organisations must not alter [section 3](#) (Characteristics of staff). **Sections 2 and 7 can be edited within the designated editable fields provided, but only for the purposes for which these sections are provided, namely the responsibilities and governance arrangements of the NHS-commissioned service using the PGD. The fields in section 2 and 7 cannot be used to alter, amend to or add to the clinical content. Such action will invalidate the UKHSA clinical content authorisation which is provided in accordance with the regulations. The legal validity of this PGD is contingent on those authorising section 2 and 7 complying with the above.**

Operation of this PGD is the responsibility of commissioners and service providers. The final authorised copy of this PGD should be kept by the authorising organisation completing [section 2](#) for 25 years after the PGD expires. Provider organisations adopting authorised versions of this PGD should also retain copies for the periods specified above.

Individual practitioners must be authorised by name, under the current version of this PGD before working according to it.

Practitioners and organisations must check that they are using the current version of the PGD. Amendments may become necessary prior to the published expiry date. Current versions of UKHSA PGD templates for authorisation can be found from: [Immunisation patient group direction \(PGD\) templates](#).

¹ This includes any relevant amendments to legislation

Any concerns regarding the content of this PGD should be addressed to:
immunisation@ukhsa.gov.uk

Enquiries relating to the availability of organisationally authorised PGDs and subsequent versions of this PGD should be directed to Vaccination Team, NHS England – Midlands, responsible for your area:

East: england.emids-imms@nhs.net

- Derby and Derbyshire
- Lincolnshire
- Leicester, Leicestershire and Rutland
- Northamptonshire
- Nottingham and Nottinghamshire

West: england.wmid-imms@nhs.net


- Herefordshire and Worcestershire
- Birmingham and Solihull
- Staffordshire and Stoke-on-Trent
- Shropshire, Telford and Wrekin
- Black Country
- Coventry and Warwickshire

Change history

Version	Change details	Date
v1.0	New UKHSA PGD template to support the delivery of the national combined measles, mumps, rubella and varicella immunisation programme to eligible children between the ages of one and under 6 years of age.	18 November 2025
v2.0	UKHSA MMRV PGD amended as follows: • clarification added to inclusion criteria, cross-referencing the advice in dose and frequency of administration, that children who have missed vaccination for MMR born on or after 1 January 2020 are in scope of this PGD • recommendation that individuals born on or after 1 January 2020, who have previously received 2 valid doses of MMR vaccine and who are not captured in the selective MMRV catch-up programme, should receive a single dose of MMRV vaccine • off-label section advice updated regarding individuals taking regular salicylates who receive a live varicella-containing vaccine, as outlined in the live monovalent varicella vaccine PGD • clarification in the dose and frequency of administration section that children born on or after 1 January 2020 and on or before 31 August 2022, who have missed routine MMR doses must not be deferred until the start of the selective MMRV catch-up programme starting 1 November 2026; offer up to 2 MMRV doses • signposting to the MMRV eligibility tables as an additional resource for those with missing MMRV doses • clarification of interval between first and second MMR-containing dose (amended from one month to 4 weeks, in line with other MMRV programme documents) • clarification that an additional MMRV dose is required at 18 months if further MMR-containing doses were offered less than 3 months after the first dose and when aged under 18 months of age (previously advised second doses offered before 15 months of age should be repeated) • minor correction made to Appendix and the brand names of monovalent varicella vaccine (Varivax® and Varilrix®, not Vaxelis® and Varilrix® as previously published)	19 January 2026

1. PGD development

This PGD has been developed by the following health professionals on behalf of the UKHSA:

Developed by:	Name	Signature	Date
Pharmacist (Lead Author)	Christina Wilson Lead Pharmacist - Immunisation Programmes –UKHSA		19 January 2026
Doctor	Dr Vanessa Saliba Consultant Medical Epidemiologist, Immunisation and Vaccine Preventable Diseases Division, UKHSA		19 January 2026
Registered Nurse (Chair of Expert Panel)	David Green Nurse Consultant Immunisation Programmes –UKHSA		19 January 2026

This PGD has been peer reviewed by the UKHSA Immunisations PGD Expert Panel in accordance with the UKHSA PGD and Protocol Policy. It has been ratified by the UKHSA Medicines Governance Committee.

Expert Panel (continued overleaf)

Name	Designation
Dr Nicholas Aigbogun	Consultant in Communicable Disease Control, Yorkshire and Humber Health Protection Team, UKHSA
Jess Baldasera	Health Protection Practitioner, North East Health Protection Team, Regions Directorate, UKHSA
Helen Beynon	Clinical Advisor, Immunisation Clinical Advice Response Service (CARS), NHS England – London
Alison Campbell	Screening and Immunisation Coordinator, Clinical, NHS England – Midlands
Laura Craig	Lead Immunisation Nurse Specialist, Immunisation Programmes – UKHSA
Jane Freeguard	Deputy Director of Vaccination – Medicines and Pharmacy, NHSE
Rosie Furner	Advanced Specialist Pharmacist – Medicines Governance (Patient Group Directions and Medicines Mechanisms), NHS Specialist Pharmacist Services (SPS)
Ed Gardner	Advanced Paramedic Practitioner/Emergency Care Practitioner, Primary Care Based, Southborne Surgery
Shilan Ghafoor	Lead Medicines Governance Pharmacist, Medicines Governance, UKHSA
Michelle Jones	Principal Medicines Optimisation Pharmacist, NHS Bristol, North Somerset and South Gloucestershire Integrated Care Board
Elizabeth Lockett	Senior Screening and Immunisation Manager, Screening and Immunisation Team – Kent and Medway, NHS England – South East
Dr Vanessa MacGregor	Consultant in Communicable Disease Control, East Midlands Health Protection Team, UKHSA

Lesley McFarlane	Lead Immunisation Nurse Specialist, Immunisation Programmes – UKHSA
Briony Mason	Vaccination Manager and Professional Midwifery Advocate, Vaccination and Screening, NHS England – West Midlands
Tushar Shah	Lead Pharmacy Adviser, NHS England – London

2. Organisational authorisation

The PGD is not legally valid until it has had the relevant organisational authorisation.

The fields in this section cannot be used to alter, amend or add to the clinical or other PGD content (sections 3 to 6 inclusive). Such action will invalidate the UKHSA clinical content authorisation which is provided in accordance with the regulations. See page 1 for full details.

It is the responsibility of the organisation that has legal authority to authorise the PGD, to ensure that all legal and governance requirements are met. The authorising body accepts governance responsibility for the appropriate use of the PGD.

NHS England authorises this PGD for use by the services or providers listed below:

Authorised for use by the following organisations and/or services
Primary care services and/or all organisations commissioned or contracted by NHS England – Midlands to provide immunisation services in: • Derby and Derbyshire • Lincolnshire • Leicester, Leicestershire, and Rutland • Northamptonshire • Nottingham and Nottinghamshire • Herefordshire and Worcestershire • Birmingham and Solihull • Staffordshire and Stoke-on-Trent • Shropshire, Telford, and Wrekin • Black Country • Coventry and Warwickshire
Limitations to authorisation
None

Organisational approval (legal requirement)			
Role	Name	Sign	Date
Regional Director of Commissioning	Roz Lindridge		21/01/2026

Additional signatories according to locally agreed policy			
Role	Name	Sign	Date

Local enquiries regarding the use of this PGD may be directed to [Local enquiries regarding the use of this PGD may be directed to: Vaccination Team, NHS England – Midlands, responsible for your area:

East: england.emids-imms@nhs.net

- Derby and Derbyshire
- Lincolnshire
- Leicester, Leicestershire and Rutland
- Northamptonshire
- Nottingham and Nottinghamshire

West: england.wmid-imms@nhs.net

- Herefordshire and Worcestershire
- Birmingham and Solihull
- Staffordshire and Stoke-on-Trent
- Shropshire, Telford and Wrekin
- Black Country
- Coventry and Warwickshire

[Section 7](#) provides a practitioner authorisation sheet. Individual practitioners must be authorised by name to work to this PGD. Alternative practitioner authorisation sheets may be used where appropriate in accordance with local policy but this should be an individual agreement or a multiple practitioner authorisation sheet as included at the end of this PGD.

3. Characteristics of staff

Qualifications and professional registration	All practitioners should only administer vaccinations where it is within their clinical scope of practice to do so. Practitioners must also fulfil the additional requirements and continued training requirements to ensure their competency is up to date, as outlined in the sections below. Practitioners working to this PGD must also be one of the following currently registered professionals who can legally supply and administer under a PGD: • nurses and midwives currently registered with the Nursing and Midwifery Council (NMC) • pharmacists and pharmacy technicians currently registered with the General Pharmaceutical Council (GPhC) (Note: This PGD is not relevant to privately provided community pharmacy services) • dieticians, occupational therapists, paramedics, physiotherapists and podiatrists currently registered with the Health and Care Professions Council (HCPC) Check section 2 (Limitations to authorisation) to confirm whether all practitioners listed above have organisational authorisation to work under this PGD.
Additional requirements	Additionally, practitioners: • must be authorised by name as an approved practitioner under the current terms of this PGD before working to it • must have undertaken appropriate training for working under PGDs for supply/administration of medicines • must be competent in the use of PGDs (see NICE Competency framework for health professionals using PGDs) • must be familiar with the vaccine product and alert to changes in the Summary of Product Characteristics (SPC), Immunisation Against Infectious Disease (the Green Book), and national and local immunisation programmes • must have undertaken training appropriate to this PGD as required by local policy and in line with the National Minimum Standards and Core Curriculum for Immunisation Training • must be competent to undertake immunisation and to discuss issues related to immunisation • must be competent in the handling and storage of vaccines, and management of the cold chain • must be competent in the appropriate administration method for the vaccines listed in this PGD • must be competent in the recognition and management of anaphylaxis • must have access to the PGD and associated online resources • should fulfil any additional requirements defined by local policy The individual practitioner must be authorised by name, under the current version of this PGD before working according to it.
Continued training requirements	Practitioners must ensure they are up to date with relevant issues and clinical skills relating to immunisation and management of anaphylaxis, with evidence of appropriate Continued Professional Development (CPD). Practitioners should be constantly alert to any subsequent recommendations from the UKHSA, NHS England and other sources of medicines information. Note: The most current national recommendations should be followed but a Patient Specific Direction (PSD) may be required to administer the vaccine in line with updated recommendations that are outside the criteria specified in this PGD.

4. Clinical condition or situation to which this PGD applies

Clinical condition or situation to which this PGD applies	Indicated for the active immunisation of individuals from one year of age for routine or catch-up immunisation, or from 9 months of age if early protection is required against varicella and recommendations given in the measles, mumps, rubella and varicella chapters of Immunisation Against Infectious Disease: the Green Book. Note: the appendix provides an overview of the scope of this and the MMR PGD.
Criteria for inclusion	1. Routine MMRV programme - all children presenting for a measles-containing vaccine with a date of birth (DOB) on or after 1 January 2020 This includes: - children who are late, have missed scheduled doses or who are unvaccinated, incompletely vaccinated or have an unknown MMR vaccination status Vaccination should not be delayed for those who have missed scheduled doses. 2. Selective MMRV catch-up programme A one-dose MMRV selective catch-up programme will be delivered between 1 November 2026 to 31 March 2028 (or other end date as subsequently communicated by NHS England). - children aged from 3 years 4 months to under 6 years on 31 December 2025 (DOB on or after 1 January 2020 to 31 August 2022) without a history of chickenpox disease or 2 doses of varicella vaccine are eligible for one dose of MMRV 3. children born on or after 1 January 2020 who have received 2 valid doses of MMR vaccine and who are not included in criterion 2 should be offered a single dose of MMRV vaccine. To provide urgent measles or varicella protection, or opportunistic MMR catch up 4. when the child is in one of the eligible cohorts as outlined above (aged 12 months and over) and protection is indicated as part of a response to a measles outbreak or for travel to a measles endemic area. 5. when an individual aged 9 months of age and over requires urgent protection against either varicella or measles, such as during an outbreak and is eligible for vaccination with the varicella vaccine (refer to the varicella vaccine PGD) or for vaccination with MMR (refer to the MMR PGD) but no stock of either is available. 6. when an individual aged 9 months of age and over requires both MMR and monovalent varicella vaccination at the same time, it is more pragmatic to give the MMRV vaccine. 7. when an individual not eligible for MMRV requires an opportunistic dose of MMR vaccine to bring their vaccination history up to date, but there is no stock of the MMR vaccine available.

Criteria for exclusion²	Individuals for whom no valid consent has been received (or for whom a best-interests decision in accordance with the Mental Capacity Act 2005, has not been obtained). For further information on consent, see chapter 2 of the Green Book. Several resources are available to inform consent (see written information to be given to individual, parent or carer section). Individuals who: • have had a confirmed anaphylactic reaction to a previous dose of any measles, mumps, rubella or varicella containing vaccine or to any components of the vaccine. These include neomycin and sorbitol (refer to relevant SPCs) • were born on or before 31 December 2019, except those who require vaccination under points 4, 5, 6 or 7 of the criteria for inclusion above • are under 9 months of age • are known to be pregnant • have a primary or acquired immunodeficiency state (see the Green Book chapter 6 for more detail) • are on current or recent high dose immunosuppressive or biological therapy (see the Green Book chapter 6 for more detail) • have received a live varicella-containing vaccine or yellow fever vaccine in the preceding 4 weeks, unless protection against measles is rapidly required (see drug interactions) • have received blood products, such as immunoglobulins, in the preceding 3 months, unless protection against measles is rapidly required (see drug interactions) • are awaiting reading of a tuberculin (Mantoux) skin test, unless protection against measles is rapidly required (see drug interactions) • are suffering from acute severe febrile illness (the presence of a minor infection is not a contraindication for immunisation) • have received 2 doses of MMRV, at an appropriate age to be effective (see also special considerations and additional information – early vaccination due to travel, outbreak or contact with a probable or confirmed case of measles)
Cautions including any relevant action to be taken (continued over page)	Facilities for management of anaphylaxis should be available at all vaccination sites (see chapter 8 of the Green Book) and advice issued by the Resuscitation Council UK. Individuals who are immunosuppressed or who are living with HIV, who are not contraindicated to receive this live vaccine (see the Green Book chapter 6) may not make a full antibody response and revaccination upon cessation of treatment or clinical recovery may be required. This should be discussed with the appropriate specialist and the repeat dose administered under a PSD. If idiopathic thrombocytopenic purpura (ITP) has occurred within 6 weeks of the first dose of MMRV, then blood should be taken and tested for measles antibodies before a second dose is given. Serum should be sent to the UKHSA Virus Reference Department, which offers free, specialised serological testing for such children. If the results suggest incomplete immunity against measles, then a second dose of MMRV is recommended.

² Exclusion under the PGD does not necessarily mean the medication is contraindicated, but it would be outside its remit and another form of authorisation will be required

Cautions including any relevant action to be taken (continued)	The presence of a neurological condition is not a contraindication to immunisation but if there is evidence of current neurological deterioration, deferral of vaccination may be considered, to avoid incorrect attribution of any change in the underlying condition. The risk of such deferral should be balanced against the risk of the preventable infection, and vaccination should be promptly given once the diagnosis or the expected course of the condition (or both) become clear. There will be very few occasions when deferral of immunisation is required. Deferral leaves the child unprotected and so the period of deferral should be minimised, with immunisation commencing as soon as possible. If a specialist recommends deferral, this should be clearly communicated to the individual's primary care provider, who must be informed as soon as the child is fit for immunisation. Children with a personal or close family history of seizures should still be given the MMRV vaccine. Priorix Tetra® and ProQuad® both contain a source of phenylalanine. Though phenylalanine may be harmful to individuals with phenylketonuria (PKU), such individuals (or their parent or carer) will be well versed as to the amounts of phenylalanine tolerable in their diet. The National Society for Phenylketonuria (NSPKU) advise the amount of phenylalanine contained in vaccines is negligible and therefore strongly advise individuals with PKU to take up the offer of immunisation. Syncope (fainting) can occur following, or even before, any vaccination especially in adolescents as a psychogenic response to the needle injection. This can be accompanied by several neurological signs such as transient visual disturbance, paraesthesia and tonic-clonic limb movements during recovery. It is important that procedures are in place to avoid injury from faints.
Action to be taken if the patient is excluded (continued over page)	Individuals who have had a confirmed anaphylactic reaction to a previous dose of MMRV vaccine or to any components of the vaccine should be referred to a clinician for specialist advice and appropriate management. Individuals who are pregnant should be advised to avoid contact with known or suspected cases of measles, mumps, rubella or varicella infection and report any rash illness or contact with rash illness to their GP or midwife (or both). Women who are lacking 2 documented doses of MMR should be immunised after their pregnancy, at the earliest opportunity and before any further pregnancies. Note: MMRV can be given to breast-feeding mothers without any risk to their baby. Individuals who have a primary or acquired immunodeficiency state or who are currently, or were recently, on high dose immunosuppressive or biological therapy (see chapter 6) should consult the appropriate specialist regarding the individual's immune status and suitability for receiving live MMRV vaccine. Where administration of MMRV is advised, a PSD will be required. Further information to guide suitability of the MMRV vaccine for individuals living with HIV is available in Table 1(CD4 count) of the Green Book chapter on measles. Individuals who have been immunised against varicella or yellow fever within the last 4 weeks, or received blood products in the preceding 3 months, and do not require rapid protection against measles, mumps or rubella, should defer immunisation until the appropriate minimum interval has been observed (see drug interactions section). Individuals who are awaiting reading of a tuberculin (Mantoux) test should delay vaccination with MMRV until the skin test has been read, unless protection against measles is required urgently. Individuals aged 6 years and over on 1 January 2026, with a DOB on or before 31 December 2019 are not routinely in scope for inclusion with the

Action to be taken if the patient is excluded (continued)	MMRV programme. If the individual has not had 2 doses of MMR vaccine, they should complete the course with the MMR vaccine. Refer to the MMR PGD. The main exception to this is in cases (as per criteria for inclusion) where there is no stock of MMR or of the monovalent varicella vaccine accessible and urgent protection is required, such as in post-exposure measles prophylaxis or where an opportunistic dose of MMR is required for an unimmunised or partially immunised individual. In such exceptions, MMRV may be given under this PGD. The other main exception is in the rare event that an individual is identified as requiring both varicella and MMR vaccination. It is considered pragmatic to offer MMRV in such circumstances. In case of postponement due to acute severe febrile illness, advise when the individual can be vaccinated and ensure another appointment is arranged. Seek appropriate advice from the local Screening and Immunisation Team, local Health Protection Team or the individual's clinician as appropriate. The risk to the individual of not being immunised must be taken into account. Document the reason for exclusion and any action taken in the individual's clinical records. Inform or refer to the GP or a prescriber as appropriate.
Action to be taken if the individual, parent or carer declines treatment	Advise the individual, parent or carer about the protective effects of the vaccine, the risks of infection and potential complications. Document the advice given and the decision reached. Inform or refer to the GP or a prescriber as appropriate.
Arrangements for referral for medical advice	As per local policy

5. Description of treatment

Name, strength and formulation of drug	Measles, mumps, rubella and varicella vaccine (live): • ProQuad® powder and solvent for suspension for injection • Priorix Tetra® powder and solvent for solution for injection
Legal category	Prescription only medicine (POM)
Black triangle▼	No.
Off-label use	The national MMRV programme is scheduled at 12 and 18 months of age. This interval of 6 months is off label, as the SPCs recommend a minimum interval of one month (6 weeks for Priorix Tetra®) and preferably 3 months between doses, but represents national guidance. The SPC for Priorix Tetra® recommends that salicylates are avoided for 6 weeks following varicella vaccination. Individuals may continue with their salicylate treatment before and after varicella vaccination in accordance with varicella chapter of the Green Book. The vaccines should be stored according to the conditions detailed in the storage section below. However, in the event of an inadvertent or unavoidable deviation of these conditions, refer to Vaccine Incident Guidance. Where vaccines are assessed in accordance with these guidelines as appropriate for continued use, this would constitute off-label administration under this PGD. Where a vaccine is recommended off-label consider, as part of the consent process, informing the individual, parent or carer that the vaccine is being offered in accordance with national guidance but outside of product licence.
Route and method of administration	The vaccine must be reconstituted in accordance with the manufacturer's instructions prior to administration. Administer by intramuscular injection, preferably into the anterolateral aspect of the thigh in infants under one year of age. The deltoid muscle of the upper arm may be used in individuals over one year of age. When administering at the same time as other vaccines, care should be taken to ensure that the appropriate route of injection is used for all the vaccinations. The vaccines should be given at separate sites, preferably into different limbs. If given into the same limb, they should be given at least 2.5cm apart. The site at which each vaccine was given should be noted in the individual's records. Individuals with bleeding disorders may be vaccinated intramuscularly if, in the opinion of a clinical familiar with the individual's bleeding risk, vaccines or similar small volume intramuscular injections can be administered with reasonable safety by this route. Individuals on stable anticoagulation therapy, including individuals on warfarin who are up to date with their scheduled INR testing and whose latest INR was below the upper threshold of their therapeutic range, can be vaccinated via the intramuscular route. If the individual receives medication or other treatment to reduce bleeding, for example treatment for haemophilia, intramuscular vaccination can be scheduled shortly after such medication or other treatment is administered. A fine needle (equal to 23 gauge or finer calibre such as 25 gauge) should be used for the vaccination, followed by firm pressure applied to the site (without rubbing) for at least 2 minutes. The individual, parent or carer should be informed about the risk of haematoma from the injection. Both MMRV vaccines are licensed to be given subcutaneously, therefore a healthcare professional may determine this is a preferred route of administration for an individual with a bleeding disorder. Note fewer injection

(continued over page)

Route and method of administration

(continued)

site reactions were reported with the intramuscular route compared with the subcutaneous route following administration of ProQuad®.

The vaccine should be visually inspected for foreign particulate matter and other variation of expected appearance prior to preparation and administration. Should either occur, do not administer the dose and discard the vaccine in accordance with local procedures.

Upon reconstitution, ProQuad® forms a clear pale yellow to light pink liquid. Priorix® Tetra forms a clear peach to fuchsia pink solution.

The vaccine [SPC](#) provides further guidance on preparation and administration.

Dose and frequency of administration

Single 0.5ml dose per administration.

The dosing schedules below assume individuals have been immunised in line with the [complete routine immunisation schedule](#), without undue delay.

For individuals who have missed routine appointments, please refer to information for healthcare professionals - [Appendix A: MMRV eligibility tables](#) – and [vaccination of individuals with uncertain or incomplete immunisation status](#) guidance and offer up to 2 MMRV doses accordingly.

Table 1: Routine MMRV programme and number of doses

	One dose schedule	2 dose schedule
DOB on or after 1 January 2025		12 months and 18 months
DOB on or after 1 July 2024 to 31 December 2024		18 months and 3 years 4 months
DOB on or after 1 September 2022 to 30 June 2024	3 years 4 months	

Table 2: Selective catch-up programme (1 November 2026 to 31 March 2028)

	One dose of MMRV*
DOB 1 January 2020 to 31 August 2022	Children without a history of chickenpox disease or 2 doses of varicella vaccination. There is no requirement to check the clinical history.

***Note:** those who have had 2 doses of the varicella vaccine privately may still receive the catch-up dose.

MMRV is not required if a child has had 2 MMR vaccines and either a history of previous chickenpox infection or 2 doses of varicella vaccine. The MMRV dose may still be given even if the child has had previous chickenpox infection or 2 doses of varicella vaccine. See also [special considerations and additional information – individuals who have already received live \(monovalent\) varicella vaccine \(including private market vaccination\)](#)

Incomplete immunisation history

Those born on or after 1 January 2020 overdue any doses of MMR-containing vaccine should be given up to 2 MMRV doses to ensure full protection against measles, mumps and rubella. The individual should be brought up to date at the earliest opportunity if routine appointments have been missed.

(continued over page)

Dose and frequency of administration (continued)	Please also refer to MMRV eligibility tables and vaccination of individuals with uncertain or incomplete immunisation status guidance. In exceptional circumstances, there may be children with a DOB from 1 January 2020 not already included in the above schedules, who have already received 2 valid doses of MMR vaccine, but who are unimmunised against varicella. For example, there may be younger children who were vaccinated early due to travel, an outbreak or where vaccination was routinely offered at 18 months, not 3 years 4 months. In such cases, children should be offered a single dose of MMRV. Incomplete immunisation history: children with a DOB between 1 January 2020 and 31 August 2022 Children who have missed doses of MMR-containing vaccine with a DOB from 1 January 2020 to 31 August 2022, should not have vaccination deferred until the start of the selective MMRV catch-up programme. These children should be brought up to date at the earliest opportunity, with a minimum interval of 4 weeks between MMRV doses where applicable. Children who have had no previous doses of MMR-containing vaccine, who receive 2 MMRV doses in this way do not need to be recalled for the selective MMRV catch-up programme. There are no safety concerns if a child is given a total of 3 MMR-containing vaccines. Early vaccination due to travel, outbreak or contact with a probable or confirmed case of measles or varicella The MMRV vaccine can be given from 9 months of age when early protection is required against varicella. MMRV should not be given to individuals below 9 months of age. Vaccination for travel or measles outbreaks in this age group should be with MMR (see also appendix). • doses of MMRV given before 12 months of age should be discounted • additional doses given before 18 months of age should be given at least 3 months apart (providing the first dose was given from 12 months of age) and should be repeated from 18 months if this is not possible • doses given from 18 months of age may be given at a 4 week interval See special considerations and additional information (early vaccination due to travel, outbreak or contact with a probable or confirmed case of measles) for further information. In cases of post-exposure measles or varicella vaccination, the dose should ideally be given within 3 days of exposure to maximise vaccine efficacy.
Duration of treatment	Up to 2 doses of 0.5ml at the recommended interval (see dose and frequency of administration above). Doses that are administered early (see above) or doses given within 4 weeks of previous yellow fever, live varicella-containing vaccine or within 3 months of receiving blood products may need to be repeated (see drug interactions section and dose and frequency of administration above).
Quantity to be supplied and administered	Single 0.5ml dose per administration.
Supplies (continued over page)	Centrally purchased vaccines for the national immunisation programme for the NHS can only be ordered via ImmForm. Vaccines for use for the national immunisation programme are provided free of charge. National stock may also be used for catch-up vaccination of individuals of any age.

Supplies (continued)	Protocols for the ordering, storage and handling of vaccines should be followed to prevent vaccine wastage (see the Green Book chapter 3).
Storage	Store between +2°C to +8°C. Store in original packaging in order to protect from light. Do not freeze. ProQuad® must be administered immediately after reconstitution, to minimise loss of potency. Discard if the reconstituted vaccine is not used within 30 minutes. Priorix Tetra® must be administered promptly following reconstitution. Vaccines that are not used immediately must be kept in the refrigerator. If not used within 24 hours, the vaccine must be discarded. In the event of an inadvertent or unavoidable deviation of these conditions, vaccines that have been stored outside the conditions stated above should be quarantined and risk assessed for suitability of continued off-label use or appropriate disposal. Refer to Vaccine Incident Guidance. Contact the vaccine manufacturer where more specific advice is required about managing a temperature excursion.
Disposal	Follow local clinical waste policy and standard operating procedures to ensure safe and secure waste disposal. Equipment used for immunisation, including used vials, ampoules, or discharged vaccines in a syringe or applicator, should be disposed of safely in a UN-approved puncture-resistant sharps box, according to local waste disposal arrangements and NHS England guidance (HTM 07-01): safe and sustainable management of healthcare waste.
Drug interactions (continued over page)	The immunological response may be diminished in those receiving immunosuppressive treatment. Vaccination is recommended even if the antibody response may be limited (see criteria for exclusion). MMRV may be given at the same time or at any time before or after other inactivated vaccines. MMRV may attenuate the response to other live vaccines; see Table 11.4 (recommended time intervals when giving more than one live attenuated vaccine) in chapter 11 of the Green Book. Where protection against measles is required rapidly, other live vaccines should be given at any interval. The response may be suboptimal if yellow fever and MMR-containing vaccines are co-administered or given within a 4 week interval; an additional dose of MMR should be considered. There are no concerns from giving the MMRV vaccine to a child who has already been vaccinated with the monovalent varicella vaccine. If protection against measles is urgently required, then the benefit of protection from the vaccine outweighs the potential interference with a tuberculin (Mantoux) test. In this circumstance, the individual interpreting the negative tuberculin test should be made aware of the recent MMRV vaccination when considering how to manage that individual. When MMRV is given within 3 months of receiving blood products, such as immunoglobulin, the response to the measles component may be reduced. This is because such blood products may contain significant levels of measles-specific antibody, which could then prevent vaccine virus replication. Where possible, MMRV should be given at least one month before or deferred until 3 months after receipt of such products. If immediate measles protection is required in someone who has recently received a blood product, MMR vaccine should still be given. To confer longer-term protection, MMR should be repeated after 3 months.

Drug interactions (continued)	A detailed list of drug interactions associated with the MMRV vaccine is available from the product's SPC .
Identification and management of adverse reactions	Adverse reaction rates with ProQuad® are either similar to or less common after a second dose than after the first dose; incidence and severity of adverse reactions following a second dose with Priorix Tetra® are broadly similar. Adverse reactions are attributed to effective replication of the vaccine viruses, with subsequent mild illness. Events due to the measles component occur 6 to 11 days after vaccination. Events due to the mumps and rubella components usually occur 2 to 3 weeks after vaccination but may occur up to 6 weeks after vaccination. Adverse events due to the varicella component may occur up to a month following vaccination. Individuals with vaccine-associated symptoms are not infectious to others, although any varicella-type rash round the injection site should be covered. Transmission of varicella vaccine virus from immunocompetent vaccinees to immunocompromised close contacts has occasionally been documented, though the risk is low. Consider giving post-exposure prophylaxis to immunosuppressed contacts where the vaccinee has a disseminated rash (see the varicella chapter of the Green Book). The most common adverse reactions are fever and injection site reactions including pain, swelling and erythema. Rash (including a measles-type and varicella-type rash) is also commonly reported. Malaise, fever or a rash (or a combination of these) most commonly occur about a week after immunisation, lasting around 2 to 3 days. Hypersensitivity reactions and anaphylaxis can occur but are very rare. Rare and more serious events Febrile seizures, benign and short lived in nature are the most commonly reported neurological event following immunisation with MMRV and more commonly after the first compared to the second dose. Seizures occur between day 5 and 12 following vaccination in around 1 in 1000 children vaccinated with MMRV. The absolute risk of febrile seizures remains low. Encephalitis has been reported during post-marketing use of MMRV vaccines. In a few cases, fatal outcomes have been observed, especially in patients who were immunocompromised. Individuals, parents or carers should be instructed to seek prompt medical attention if they or their child experience symptoms suggestive of encephalitis such as loss or reduced levels of consciousness, convulsions or ataxia accompanied by fever and headache. Arthropathy (arthralgia or arthritis) has also been reported to occur rarely after MMR immunisation, probably due to the rubella component. If it is caused by the vaccine, it should occur between 14 and 21 days after immunisation. Where it occurs at other times, it is highly unlikely to have been caused by vaccination. The incidence rate is higher and the reaction more marked in adult females, though such reactions are generally well tolerated. ITP has occurred rarely following MMRV vaccination, usually within 6 weeks of the first dose and resolves spontaneously. The risk of developing ITP after MMRV vaccine is much less than the risk of developing it after infection with wild measles or rubella virus (see cautions). Further details on adverse reactions following MMRV vaccine can be found in the Green Book chapters on measles, mumps, rubella and varicella. A detailed list of adverse reactions associated with the MMRV vaccine is available from the product's SPC.

Reporting procedure of adverse reactions	Healthcare professionals and individuals, parents or carers are encouraged to report suspected adverse reactions to the Medicines and Healthcare products Regulatory Agency (MHRA) using the Yellow Card reporting scheme or by searching for MHRA Yellow Card in the Google Play or Apple App Store. Any adverse reaction to a vaccine should be documented in the individual's record and the individual's GP should be informed.
Written information to be given to individual or parent (or carer)	Offer the marketing authorisation holder's patient information leaflet (PIL) provided with the vaccine. Priorix Tetra® PIL ProQuad® PIL For resources in accessible formats and alternative languages, please visit Find Public Health resources. Where applicable, inform the individual, parent or carer that large print, Braille or audio CD PILs may be available from emc accessibility by providing the medicine name and product code number, as listed on the product's SPC. Immunisation promotional material may be provided as appropriate: • MMR for all • pre-school immunisations: guide to vaccinations (2 to 5 years) • measles: information for schools and healthcare centres • measles outbreak resources
Advice and follow up treatment	Inform the individual, parent or carer of possible side effects and their management. Advise about likely timing of and subsequent management of a fever. Advise where relevant that pregnancy should be avoided for one month post vaccination. The individual, parent or carer should be advised to seek medical advice in the event of an adverse reaction and report this via the Yellow Card reporting scheme. When administration is postponed, advise the individual, parent or carer when to return for vaccination. Where applicable, advise the individual, parent or carer when the subsequent dose is due.
Special considerations and additional information (continued over page)	Ensure there is immediate access to adrenaline (epinephrine) 1 in 1000 injection and access to a telephone at the time of vaccination. All children with an egg allergy should receive the MMRV vaccination as a routine procedure in primary care. Monovalent varicella vaccines and the varicella component of MMRV are not manufactured using eggs or egg-derived products. Although MMR-containing vaccines use egg-derived products in the manufacturing process, they are not used in the vaccine itself. ProQuad® contains porcine gelatine. Priorix® Tetra (GSK) does not contain porcine gelatine and can be offered as an alternative to ProQuad®. Health professionals should be aware of the need to order Priorix® Tetra when running clinics for relevant communities (see vaccines and porcine gelatine leaflet). MMRV vaccine is recommended when protection against measles, mumps, rubella or varicella (or a combination of the 4) is required. MMRV vaccine can be given irrespective of a history of measles, mumps, rubella or varicella infection or vaccination. There are no ill effects from vaccinating those who are

MMRV vaccine PGD v2.0	Valid from: 20 January 2026	Expiry: 30 November 2028	Page 19 of 24
-----------------------	-----------------------------	--------------------------	---------------

Special considerations and additional information (continued)	Ensure an interval of at least 4 weeks is observed between live varicella vaccine and MMRV. Chickenpox infection There is no requirement to check for a history of chickenpox infection from the parent or carer of a child who responds to the catch-up offer. There are no safety concerns from giving MMRV to a child who has already had chickenpox infection. Post exposure Antibody responses to the rubella and mumps components of MMRV vaccine do not develop soon enough to provide effective prophylaxis after exposure to these infections. However, as vaccine-induced measles antibody develops more rapidly than that following natural infection, MMRV vaccine should be used to protect susceptible contacts from suspected measles. To be effective against measles or varicella exposure, the vaccine must be administered very promptly and ideally within 3 days. Even where it is too late to provide effective post-exposure prophylaxis with MMRV, the vaccine can provide protection against future exposure. Therefore contact with suspected measles, mumps, rubella or varicella provides a good opportunity to offer MMRV vaccine to previously unvaccinated, eligible individuals. If the individual is already incubating measles, mumps, rubella or varicella, MMRV vaccination will not exacerbate the symptoms. In these circumstances, individuals should be advised that a measles, mumps, rubella or varicella-like illness occurring shortly after vaccination is likely to be due to natural infection. Immunoglobulin may be indicated for contacts of measles who are infants, immunosuppressed or pregnant or for some varicella contacts. Provision of immunoglobulin is not covered by this PGD (see national measles guidelines or guidelines on post-exposure prophylaxis (PEP) for varicella or shingles respectively).
Records (continued over page)	The practitioner must ensure the following is recorded: • that valid informed consent was given or a decision to vaccinate made in the individual's best interests in accordance with the Mental Capacity Act 2005 • name of individual, address, date of birth and GP with whom the individual is registered (or record where an individual is not registered with a GP) • name of immuniser • name and brand of vaccine • date of administration • dose, form and route of administration of vaccine • quantity administered • batch number and expiry date • anatomical site of vaccination • advice given, including advice given if the individual is excluded or declines immunisation • details of any adverse drug reactions and actions taken • supplied via PGD Records should be signed and dated (or password-controlled on e-records). All records should be clear, legible and contemporaneous. This information should be recorded in the individual's GP record. Where vaccine is administered outside the GP setting, appropriate health records should be kept and the individual's GP informed.

Records (continued)	The local Child Health Information Systems (CHIS) team must be notified using the appropriate documentation or pathway as required by any local or contractual arrangement. A record of all individuals receiving treatment under this PGD should also be kept for audit purposes in accordance with local policy.
-------------------------------	--

6. Key references

Key references	MMRV vaccine - Immunisation Against Infectious Disease: The Green Book measles, mumps, rubella and varicella, chapter 6 and chapter 11 www.gov.uk/government/collections/immunisation-against-infectious-disease-the-green-book - Introduction of a routine varicella (MMRV) vaccination programme (NHS system letter), published 31 October 2025 https://www.gov.uk/government/publications/introduction-of-a-routine-varicella-mmr-vaccination-programme - Summary of Product Characteristics for ProQuad®, Merck Sharpe and Dohme, last updated 7 October 2025 https://www.medicines.org.uk/emc/product/101444/smpc - Summary of Product Characteristics for Priorix Tetra®, GlaxoSmithKline, last updated 31 October 2025 https://www.medicines.org.uk/emc/product/101321/smpc - JCVI: Childhood varicella vaccination programme: JCVI advice, 14 November 2023 https://www.gov.uk/government/publications/childhood-varicella-vaccination-programme-jcvi-advice-14-november-2023 - MSD Medical Information, Personal communication (via email), 13 December 2023 - UKHSA national measles guidelines, last updated 25 July 2024. https://www.gov.uk/government/publications/national-measles-guidelines - Vaccination of individuals with uncertain or incomplete immunisation status, UKHSA www.gov.uk/government/publications/vaccination-of-individuals-with-uncertain-or-incomplete-immunisation-status - The National Society for Phenylketonuria (NSPKU) Medical Advisory Panel: Vaccines and PKU, issued 2 October 2024 https://nspku.org/download/vaccines-and-pku/ General - NHSE Health Technical Memorandum 07-01: safe and sustainable management of healthcare waste, updated 7 March 2023 www.england.nhs.uk/publication/management-and-disposal-of-healthcare-waste-htm-07-01/ - National minimum standards and core curriculum for vaccination training www.gov.uk/government/publications/national-minimum-standards-and-core-curriculum-for-immunisation-training-for-registered-healthcare-practitioners - NICE Medicines Practice Guideline 2 (MPG2): Patient Group Directions, last updated March 2017 www.nice.org.uk/guidance/mpg2 - NICE MPG2 Patient group directions: competency framework for health professionals using patient group directions, updated January 2018 www.nice.org.uk/guidance/mpg2/resources - UKHSA Immunisation Collection www.gov.uk/government/collections/immunisation - Vaccine Incident Guidance, last updated July 2022 www.gov.uk/government/publications/vaccine-incident-guidance-responding-to-vaccine-errors
----------------	---

7. Practitioner authorisation sheet

MMRV vaccine PGD v2.0 Valid from: 20 January 2026 Expiry: 30 November 2028

Before signing this PGD, check that the document has had the necessary authorisations in section 2. Without these, this PGD is not lawfully valid.

Practitioner

By signing this PGD, you are indicating that you agree to its contents and that you will work within it. PGDs do not remove inherent professional obligations or accountability.

It is the responsibility of each professional to practice only within the bounds of their own competence and professional code of conduct.

I confirm that I have read and understood the content of this PGD and that I am willing and competent to work to it within my professional code of conduct.			
Name	Designation	Signature	Date

Authorising manager

I confirm that the practitioners named above have declared themselves suitably trained and competent to work under this PGD. I give authorisation on behalf of insert name of organisation for the above-named healthcare professionals who have signed the PGD to work under it.			
Name	Designation	Signature	Date

Note to authorising manager

Score through unused rows in the list of practitioners to prevent practitioner additions post managerial authorisation.

This authorisation sheet should be retained to serve as a record of those practitioners authorised to work under this PGD.

Appendix: PGD indications for use for MMR, MMRV and monovalent varicella vaccine, in accordance with the individual's age.

	6 to 9 months of age	9 months to less than 12 months of age	12 months of age and over
Monovalent varicella vaccine (V) PGD	Not recommended	Recommended vaccine for pre and post exposure to varicella	Recommended vaccine for pre and post exposure to varicella, where the individual is not eligible for the MMRV programme
MMR PGD	Indications for PGD unchanged: - early vaccination for travel to a measles endemic area - post exposure prophylaxis for measles - measles outbreaks	Indications for PGD unchanged: - early vaccination for travel to a measles endemic area - post exposure prophylaxis for measles - measles outbreaks	The individual is ineligible for the MMRV programme and either MMR protection is required in line with the vaccination of individuals with uncertain or incomplete immunisation algorithm or for travel, post exposure or outbreak
MMRV PGD	Not recommended	Alternative option for varicella pre and post-exposure, where Varivax® or Varilrix® is not available and protection is urgently required	Routine vaccination at 12 and 18 months for children born on or after 1 January 2025; bringing MMRV status up to date for children born on or after 1 January 2020 Individuals ineligible for MMRV, when MMR or monovalent varicella vaccine is not available* and who require urgent protection against MMR or V, such as in managing post-exposure varicella or measles outbreaks or administering an opportunistic catch-up dose of MMR vaccine. Where an individual requires both varicella vaccine and MMR vaccine at the same time, even if they are not eligible for MMRV in the routine programme.

*MMR vaccine will be available for administration outside of the routine childhood programme (for example, for catching up older individuals, where date of birth is on or before 31 December 2019, who have not received 2 doses of MMR and are not eligible for MMRV). Therefore, after 1 January 2026, providers are expected to maintain stock of MMR vaccine for those ineligible for MMRV.